Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. STOCKS ON THE MOVE-Lands' End, City National, Covenant

Thu, 22nd Jan 2015 14:20

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s) U.S. stock index futures pointed to modest gains at the open onThursday after the European Central Bank announced expandedmeasures to stimulate the region's economy. Dow Jones industrialaverage e-mini futures were up 0.54 percent at 17,585,S&P 500 e-mini futures were up 0.64 percent at 2,039.5and Nasdaq 100 e-mini futures were up 0.55 percent at4,205.75.

** LANDS' END INC , Wednesday close $50.71, -21.91pct premarket

The apparel retailer forecast lower revenue from merchandisesales and services in the fourth quarter. "We were disappointedby the performance of our cold weather assortment, especiallyduring the peak holiday period," Chief Executive Edgar Hubersaid. International business was affected by unfavorable changesin currency exchange rates and lower sales in Europe. Thecompany, spun off from Sears Holdings Corp last year,forecast Q4 earnings much below analysts' average estimate.

** CITY NATIONAL CORP, Wednesday close$74.57, +18.40 pct premarket

Royal Bank of Canada said it would buy theU.S. lender serving high net worth clients in a cash-and-stockdeal valued at $5.4 billion. RBC offered $47.25 in cash and0.7489 in shares for each City National share. The total offerof $93.80 per share, based on RBC's closing price of $62.16 onthe New York Stock Exchange on Wednesday, represents a premiumof nearly 26 percent to City National's last closing price.

** F5 NETWORKS INC, Wednesday close $125.95, -14.41pct premarket

The network equipment maker reported revenue that missedWall Street's estimates for the first time in eight quarters dueto "a marked decrease in the number of deals greater than $1million".

At least 8 brokerages cut price targets on the stock by asmuch as $25 to as low as $105; Median target price $133

"Comps become much more difficult in the coming quarters andthe company will have to prove that newer initiatives likesecurity can drive revenue re-acceleration and sustainabledouble-digit growth" Barclays analysts wrote in a note.

** LOGITECH INTERNATIONAL SA, Wednesday close$14.09, +8.16 pct premarket

The company increased profitability outlook for full year2015. The traders cited strong EBIT number of $76.4 mln for thethird quarter. The stock was the top riser on Stoxx 600, with a full-day's 30-day average volume alreadytraded.

** PETROBRAS , Wednesday close $7.35, +5.71 pctpremarket

** TOTAL SA , Wednesday close $51.64, +0.35 pctpremarket

** BP Plc , Wednesday close $38.82, +0.41 pctpremarket

** HALLIBURTON CO , Wednesday close $40.69, +0.27pct premarket

** SCHLUMBERGER LTD , Wednesday close $82.21, +0.57pct premarket

** SEADRILL LTD , Wednesday close $10.38, +3.37 pctpremarket

** TRANSOCEAN LTD , Wednesday close $16.06, +1.49pct premarket

** NABORS INDUSTRIES LTD , Wednesday close$10.86, +1.20 pct premarket

Brent crude rose ahead of an expected decision by EuropeanCentral Bank to start buying bonds, a move which could pushdollar to new highs and put downward pressure on commodities.Brent crude up 2 pct at $49.99 per barrel; U.S. crude up 1.5 pct at $48.49 per barrel.

** BLACKBERRY LTD, Wednesday close $9.93, +5.54 pctpremarket

Samsung Electronics Co Ltd is actively pursuinga plan to take over or buy a significant stake in the canadiancompany despite statements from both companies this weekdenying that such a plan may be in the works, Canada's FinancialPost reported. (http://bit.ly/1wpG0Ue)

** XILINX INC, Wednesday close $41.51, -7.25 pctpremarket

The programmable-chip maker's shares forecast Q3 revenue andQ4 revenue below analysts' average estimates. Results andforecast hurt by weak sales to broadcast and communicationscustomers.

At least nine brokerages cut price targets, with Robert W.Baird & Co slashing by $8.00 to $44.00

** MEDIVATION , Wednesday close $111.2, -3.39 pctpremarket

The drug developer says its prostate cancer therapy Xtandiwas not as safe as AstraZeneca Plc's treatment Casodexin a mid-stage study. 31 pct patients given Xtandi had seriousadverse reactions compared with 23.3 pct patients who were givenCasodex. Xtandi increased the time patients survived withoutprogression of the disease to 15.7 months, compared to 5.8months among Casodex patients.

** COVENANT TRANSPORTATION, Wednesday close$24.76, +9.05 pct premarket

The transportation services provider's Q4 earnings 82 centsper share came above the average analyst estimate 74 cents. Peakholiday shipping, lower fuel costs boosted profit, CEO DavidParker said.

** SANDISK CORP, Wednesday close $80.44, -6.51 pctpremarket

The memory chip maker forecast current-quarter andfull-year 2015 revenue well below Wall Street expectations,saying it would be unable to meet demand for flash memorystorage chips until mid-year due to lean inventory levels.

** KERYX BIOPHARMACEUTICALS INC, Wednesday close$12.87, -2.41 pct premarket

The drug developer's offering of 9.2 mln shares priced at$12 each, a discount of 6.8 pct to Wednesday's close. Thecompany, which had 91.9 mln shares outstanding as of Wednesday'sclose, said it would use $110 mln proceeds to fund marketing ofrecently approved chronic kidney disease treatment Auryxia.

** INTREXON CORP, Wednesday close $28.4, -1.37 pctpremarket

The synthetic biology company's offering of 3.8 millionshares priced at $27.00 each, a discount of 4.9 pct to thestock's Wednesday's closing price. Company had about 100.5 mlnshares outstanding as of Wednesday, according to Thomson Reutersdata.

** BIOMARIN PHARMACEUTICAL INC, Wednesday close$96.14, -2.86 pct premarket

The drugmaker's offering of 8.5 mln shares priced at $93.25each, a 3 pct discount to the stock's Wednesday close. THecompany had 147.4 mln shares outstanding as of Sept. 30,according to Thomson Reuters data. Says to use net proceeds tofund acquisition of Dutch drug developer Prosensa Holding NV and for general corporate purposes.

** AMERICAN EXPRESS CO, Wednesday close$87.67, -2.69 pct premarket

The world's largest credit card issuer will cut more than4,000 jobs this year, an executive said, after the credit cardcompany also reported higher quarterly expenses and provisionsfor bad loans. The planned redundancies, from a workforce ofnearly 63,000, contributed to a $313 million pre-taxrestructuring charge.

Jefferies cuts price target to $90 from $95, Barclays to $96from $100, and Bernstein to $97 from $99.

** EBAY INC, Wednesday close $53.38, +3.03 pctpremarket

The company plans to break up into three different companiesto accommodate would-be suitors, signaling a potential mergerfight after the breakup.

The company plans to spin off its payments division,PayPal, from its core marketplace division in the second half ofthe year, making two standalone publicly traded companies thatsome analysts say could be worth more than the combinedentity.

Cowen and Co raises price target to $57 from $55, RBCCapital Markets to $58 from $55 and Susquehanna Financial Groupto $59 from $52.

** VERIZON COMMUNICATIONS INC, Wednesday close$48.25, -0.41 pct premarket

THe company's quarterly revenue rose 6.8 percent due tohigher net addition of postpaid subscribers and a rise inaverage revenue per account as users added more devices toshared data plans. The company, however, reported a loss of$2.15 billion, or 54 cents per share, for the fourth quartercompared with a profit of $7.92 billion, or $1.76 per share, ayear earlier, mainly due to valuation of benefits plan andpension adjustments.

** MICROSOFT CORP, Wednesday close $45.92, +0.78pct premarket

The ageing tech pioneer surprised the tech world onWednesday with a prototype hologram visor that can bring theMinecraft video game, Skype calls and even the landscape of Marsto three-dimensional life.

** SALLIE MAE CORP, Wednesday close $9.69, -13.21pct premarket

The provider of student loans forecasted 2015 EPS of 48-50cents below analysts average estimate of 62 cents, according toThomson Reuters I/B/E/S. Net income for the fourth quarterplunged 75 pct to $14.9 million, missing analysts' averageestimate. Provision for loan losses rises 7 pct to $30 millionin Q4.

** FAMILY DOLLAR STORES INC, Wednesday close $75.55

The shareholders are expected to vote in favor of a pending$8.5 billion merger with Dollar Tree Inc despite ahigher offer from Dollar General still on the table,according to people familiar with the matter.

The vote, which is scheduled for Thursday, comes afterinfluential proxy advisory firm Institutional ShareholderServices said Dollar Tree's proposal was in the best interest ofshareholders and was more likely to close as it faces fewerantitrust hurdles than the Dollar General offer. (Compiled by Rosmi Shaji in Bengaluru; Edited by Don Sebastian)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.